In Addition it raises execution threat since new builds will have to recruit and educate scarce method engineers. If FDA anticipations tighten for info integrity, Merck's scale and high-quality techniques should support protect continuity. A downside circumstance is slower ramp timing that forces greater dependence on external drug compound partners. https://www.tjcy.com/industry-information/api-vs-fdf-vs-intermediates-what-s-the-difference.html